InstalabLoading...
InstalabLoading...
An antibody your immune system produces in response to a nearly universal childhood virus, signaling either a recent first infection or a reactivation that may need clinical context to interpret.
Almost everyone on the planet has been infected with HHV-6 (human herpesvirus 6) by the time they turn two. The virus quietly takes up permanent residence in the body, and for most people, it never causes trouble again. But in certain situations, particularly in young children during their first encounter with the virus or in people whose immune systems are suppressed, HHV-6 can flare up and cause real problems. The HHV-6 IgM test looks for a specific type of antibody your immune system makes when it is actively fighting this virus, either for the first time or during a reactivation.
A positive result suggests your immune system is mounting a fresh response to HHV-6 right now. But because this virus is so common and the antibody can appear during both first infections and reactivations, a single positive IgM result on its own does not tell you whether you are dealing with a new infection, a flare-up of an old one, or even a lingering antibody from a past encounter. That makes context everything with this test.
Your immune system produces different classes of antibodies at different stages of an infection. IgM antibodies are typically the first responders. They rise early during an infection and then fade over weeks. IgG antibodies arrive later and tend to stick around for life, serving as a record of past exposure. The HHV-6 IgM test measures whether those early-response antibodies are circulating in your blood.
The complication is that HHV-6 IgM antibodies can appear during both a primary infection (your first encounter with the virus) and a reactivation (when the dormant virus wakes up later in life). This means a positive IgM result does not automatically distinguish between those two very different scenarios. A fourfold rise in IgG antibody levels using paired blood samples drawn weeks apart, or the demonstration of IgG seroconversion from negative to positive, provides stronger evidence of a recent infection.
This is not a highly precise test. In one study of children with confirmed recent primary infection, the HHV-6 IgM test caught about 76 out of every 100 true cases and correctly identified about 88 out of every 100 people who were not recently infected, with an overall accuracy of only 82.4%. A specialized version of the test called a mu-capture ELISA performed better on specificity, correctly clearing about 97 to 98 out of every 100 uninfected samples, with no false positives triggered by related viruses like CMV or EBV.
What this means for you: if your IgM result is positive, there is roughly a 1-in-8 chance it is a false alarm in otherwise healthy populations. And if it is negative, there is still about a 1-in-4 chance you could have a real infection that the test missed. This is why clinicians and guidelines consistently prefer molecular testing (PCR-based detection of viral DNA) over serology for diagnosing active HHV-6 disease.
There is another wrinkle worth knowing about. Roughly 1% of the population carries HHV-6 DNA physically integrated into their own chromosomes, a condition called chromosomally integrated HHV-6. This can produce persistently high viral DNA levels in every cell of the body, leading to false-positive results on PCR tests. Standard commercial assays also do not distinguish between the two variants of the virus, HHV-6A and HHV-6B, which can have different clinical implications. Certain lab factors can occasionally affect serologic results as well.
For most healthy adults, HHV-6 testing is unnecessary. The virus was acquired in early childhood, your immune system keeps it in check, and it causes no symptoms. But there are specific groups where this test, or more often PCR-based testing, becomes clinically important.
Current guidelines from the American Society of Transplantation do not recommend routine screening for HHV-6 in transplant recipients who feel well. Instead, they recommend testing when symptoms suggest the virus may be causing problems, using quantitative PCR in blood or spinal fluid as the preferred method.
Because more than 90% of adults carry HHV-6 antibodies from childhood infection, a single positive IgG result tells you almost nothing; it simply confirms you were exposed at some point, like nearly everyone else. A positive IgM result is more informative but still ambiguous. It suggests your immune system is actively responding to HHV-6, but it cannot tell you whether this is a brand-new infection, a reactivation of a dormant virus, or a residual antibody from a recent past encounter.
The strongest serologic evidence of a recent infection comes from paired blood samples drawn two to four weeks apart showing either a conversion from negative to positive IgG (seroconversion) or a fourfold rise in IgG levels. If you or your clinician suspect active HHV-6 disease, quantitative PCR testing of blood or spinal fluid is the recommended next step and provides more actionable information than antibody testing alone.